retinitis

CMV retinitis is a slow and progressive disease in patients with advanced stage HIV.

Permanent visual impairment in children with CMV retinitis may be prevented by timely diagnosis and treatment.

Immune Recovery Uveitis was seen in twenty one eyes with CMV retinitis.

1,2] CMV retinitis is the most common manifestation of end-organ CMV disease among patients with AIDS.

2 cases of anterior uveitis were concurrent with CMV retinitis which was most probably because of the immune recovery rather than the CMV disease process itself as anterior uveitis is very rare because of CMV retinitis.

These appearances were consistent with a first presentation of CMV retinitis.

Valganciclovir is indicated for the treatment of CMV retinitis in patients with AIDS.

CMV retinitis may occur in the late stages of HIV disease, usually with a T cell count of less than 50.

Four AIDS medicines were approved by the FDA in the last year: the first in a new class of medicines called nucleotides (which in clinical trials proved effective in patients who had developed resistance to other drugs), a therapy for an AIDS-related fungal infection, a medicine for AIDS-related CMV retinitis (which can lead to blindness) and a drug that combines three antiretroviral medicines into a single tablet.

Persons with HIV infection or AIDS may develop severe CMV infections, including CMV retinitis, an eye disease that can lead to blindness.

Approved on August 26, 1998 for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are intolerant of or have a contraindication to other treatment(s) for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis.

People with AIDS are vulnerable to CMV retinitis because their immune systems are weakened.

Isis devised such a compound and gave it to about 12 patients with CMV retinitis.

At the time of this review, foscarnet has been approved for the treatment of CMV retinitis.

As a result of these and other investments, physicians and patients may now or in the future gain access to drugs for such rare diseases and disorders as pituitary dwarfism, pneumocystis carinii pneumonia, Hodgkins disease, osteosarcoma, leukemia, schistosomiasis, manic-depression, neonatal shunt cynanosis, Tourette's syndrome, Cushing's syndrome, angioedema, Wilson's disease, sickle cell anemia, candida and cryptococcus infections, colon cancer, lymphoma, Sjogren's syndrome, septic shock, toxoplasmosis, Lyme disease, carcinoid syndrome, third line testicular cancer, primary brain malignancies, CMV retinitis, hyaline membrane disease, phanylephrine, regimentary glaucoma, vernal kerato-conjunctivitis, and AIDS.